Amicus Therapeutics Announces Issuance of New Plicera Composition of Matter Patent.Amicus AMICUS Automated Management Information Civil Users System Therapeutics (Cranbury, NJ) announced the issuance on March 10, 2009 of United States Patent 7,501,439, titled "Tartrate tartrate /tar·trate/ (tahr´trat) a salt of tartaric acid. tar·trate n. A salt or ester of tartaric acid. tartrate a salt of tartaric acid. Salt of Isofagomine and Methods of Use." The patent covers the tartrate salt form of isofagomine, the active ingredient in the company's investigational drug Plicera (afegostat tartrate), and its use for the treatment of Gaucher disease Gaucher Disease Definition Gaucher disease is a rare genetic disorder that results in accumulation of fatty molecules called cerebrosides. It can have serious effects on numerous body organs including the liver, spleen, bones and central nervous system. . The patent will expire in 2027. John F. Crowley, President and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of Amicus, commented, "The issuance of this patent further strengthens our protection in the United States for Plicera in Gaucher and is one example of our ongoing efforts to establish a comprehensive intellectual property portfolio for our development programs and our pharmacological chaperone technology platform." Plicera is currently being studied in an ongoing Phase 2 study in patients naive to enzyme replacement therapy Enzyme replacement therapy is a medical treatment replacing an enzyme in patients in whom that particular enzyme is deficient or absent. Usually this is done by giving the patient an intravenous (IV) infusion containing the enzyme. . This six-month study is designed to evaluate safety and to demonstrate trends of efficacy, as measured by the standard endpoints in Gaucher disease. Amicus previously reported that enrollment has been completed for the study and the company expects the results to be available in the third quarter of 2009. Amicus is developing Plicera as part of a strategic collaboration with Shire Human Genetic Therapies (HGT HGT Height HGT Harlem Globetrotters HGT Harmonic Greedy Triplets HGT Hudson Guild Theatre (New York, NY) HGT Hand Geometry Technology HGT High Grand Touring ), a business unit of Shire plc, to develop and commercialize Amicus' three lead pharmacological chaperone compounds for lysosomal lysosomal pertaining to or emanating from lysosomes. lysosomal enzymes enzymes located in the lysosomes. lysosomal phospholipidosis storage disorders. Under the collaboration, Shire received commercial rights outside of the United States. Amicus retains all United States rights. Amicus Therapeutics is a biopharmaceutical company developing novel, oral therapeutics known as pharmacological chaperones for the treatment of a range of human genetic diseases. Pharmacological chaperone technology involves the use of small molecules that selectively bind to and stabilize proteins in cells, leading to improved protein folding and trafficking, and increased activity. Amicus is initially targeting lysosomal storage disorders, which are severe, chronic genetic diseases with unmet medical needs. Amicus Therapeutics +1-609-662-5084, www.amicustherapeutics.com |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion